What’s ahead for Eli Lilly and Novo as RFK Jr. takes over HHS
Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...
ENDPOINTS NEWS22h
Lil­ly’s ear­ly blad­der can­cer da­ta hint at safe­ty edge over J&J’s Balver­sa
Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Why Eli Lilly and Company (LLY) is the Best Long-Term Growth Stock to Buy Now
We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...
BioSpace3d
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...
FierceBiotech5d
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Eli Lilly and Company: Lilly reports full Q4 2024 financial results and provides 2025 guidance
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...